The health returns on investment in cancer research

01 May 2008
Share this page Email this page to a friend Share this page via Twitter Share this page via Facebook Share this page via LinkedIn

This report estimates the economic value of cancer research and development in NSW and Australia, using return on investment analysis.

Around $170 billion in health benefits will be delivered in the next decade to NSW if cancer death rates continue to fall.

Around one in every five years of healthy life lost in Australia are lost to cancer and it accounts for one-third of the Australian mortality burden. Although cancer mortality rates are falling, incidence is increasing, and a substantial research effort is invested in New South Wales (NSW), Australia and the world to reverse cancer's growing share of lost wellbeing.

This report estimates the economic value of cancer research and development  in NSW and Australia, using return on investment analysis. The methodology and key parameters are based to some extent on those developed in Access Economics (2003), Exceptional Returns: The Value of Investing in Health R&D in Australia, bearing in mind that report was for all health R&D, while this report relates more specifically to cancer R&D.

Top of page